What is NovoCure's EBITDA?

NovoCure (NVCR) reported EBITDA of -$63.3M in Q1 2026.

How has NovoCure's EBITDA changed year-over-year?

NovoCure's EBITDA decreased by 83.3% year-over-year, from -$34.54M to -$63.3M.

What is the long-term trend for NovoCure's EBITDA?

Over 4 years (2021 to 2025), NovoCure's EBITDA has grown at a 42.1% compound annual growth rate (CAGR), from -$34.08M to -$139.15M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.

NovoCure NVCR EBITDA

EBITDA at other companies

Iovance Biotherapeutics, Inc.IOVA

-$78.22M+34.1%

Vir Biotechnology, Inc.VIR

-$129.48M+5.3%

Syndax PharmaceuticalsSNDX

-$30.2M+63.9%

ArriVent BioPharma, Inc.AVBP

-$46.67M+30.9%

Boston ScientificBSX

——

MedtronicMDT

——

Other financials

Income statement

See full

Revenue$174.1M+12.3%

Gross profit$135.1M+16.0%

Operating income-$67.4M-78.1%

Net income-$71.1M-107%

EPS (diluted)-$0.62-100%

Balance sheet

See full

Cash & equivalents$87.5M-31.2%

Total debt$39.5M-2.1%

Total equity$330.7M-8.6%

Total assets$787.9M-36.9%

Cash flow

See full

Operating cash flow-$13.5M+62.1%

CapEx$5.2M-51.4%

Free cash flow-$18.7M+59.7%

Valuation

See full

Market cap$1.7B-36.7%

Enterprise value$1.66B-36.3%

P/S2.5×-1.8×

Profitability

See full

Gross margin75.2%-2.0pp

Operating margin-27.2%+0.4pp

Net margin-25.7%-0.7pp

FCF margin-7.1%-2.0pp

Returns & leverage

See full

Return on equity-50%+5.4pp

Debt / equity0.1×0.0×

Current ratio2.9×+1.4×

Where this comes from

Calculated from NovoCure’s reported figures.

−$67.4Mebit+

$4.1MDepreciation Depletion & Amortization

=-$63.3M

The official record: NovoCure’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about NovoCure's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NovoCure's EBITDA?: NovoCure (NVCR) reported EBITDA of -$63.3M in Q1 2026.
How has NovoCure's EBITDA changed year-over-year?: NovoCure's EBITDA decreased by 83.3% year-over-year, from -$34.54M to -$63.3M.
What is the long-term trend for NovoCure's EBITDA?: Over 4 years (2021 to 2025), NovoCure's EBITDA has grown at a 42.1% compound annual growth rate (CAGR), from -$34.08M to -$139.15M.
What does EBITDA mean?: Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.